

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 November 2009 (05.11.2009)

PCT

(10) International Publication Number
WO 2009/134718 A8

(51) International Patent Classification:

A61K 31/56 (2006.01) *A61P 15/04* (2006.01)
A61P 15/00 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/US2009/041826

(22) International Filing Date:

27 April 2009 (27.04.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/048,472 28 April 2008 (28.04.2008) US

(71) Applicant (for all designated States except US): **RE-PROS THERAPEUTICS INC.** [US/US]; 2408 Timberloch Place, Suite B-7, The Woodlands, TX 77380 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **PODOLSKI, Joseph, S.** [US/US]; 3 Pebble Hollow Court, The Woodlands, TX 77381 (US).

(74) Agent: **CLOUGH, David, W., Ph. D.**; Howrey LLP, Docketing Department, 2941 Fairview Park Drive, Suite 200, Falls Church, VA 22042 2924 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(48) Date of publication of this corrected version:

23 September 2010

(15) Information about Correction:

see Notice of 23 September 2010

(54) Title: PROGESTERONE ANTAGONISTS SUCH AS CDB-4124 IN THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, DYSMENORRHEA, BREAST CANCER ETC

(57) Abstract: The present invention relates to methods of administering compositions comprising a progesterone receptor antagonist for use in treating estrogen-dependent conditions. The invention is also directed to methods for treating pain associated with endometriosis. The compositions may be administered to females with endometriosis as well as to females undergoing estrogen and/or selective estrogen receptor modulator (SERM) therapy. In certain embodiments, the invention provides a method for suppressing endometrial proliferation.



WO 2009/134718 A8